GO:0035194 regulatory ncRNA-mediated post-transcriptional gene silencing: RNAi Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035194 describes a post-transcriptional gene silencing pathway in which regulatory non-coding RNAs (ncRNAs) silence specific target genes by mRNA destabilization or translational inhibition.
• The term encompasses RNA interference (RNAi), microRNA-mediated silencing, cosuppression, quelling, and related RNA-dependent silencing phenomena.
• Core molecular players include Dicer, Argonaute, TRBP, and other RNA-induced silencing complex (RISC) components that process and execute silencing.
• RNAi has become a powerful research tool for loss-of-function studies and a therapeutic modality, with nucleic acid therapeutics entering clinical use.
• Dysregulation of ncRNA-mediated silencing is implicated in cancer, viral infection, and neurological disorders, making it a key area for disease modeling.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of genes involved in this pathway for basic and translational research.
Description
Regulatory non-coding RNA (ncRNA)-mediated post-transcriptional gene silencing, classified as GO:0035194, is a fundamental biological process that controls gene expression after transcription. It includes RNA interference (RNAi), microRNA (miRNA)-mediated silencing, and related pathways where small regulatory RNAs guide the sequence-specific repression of target mRNAs. This process is conserved across eukaryotes and is essential for development, genome stability, and defense against foreign nucleic acids. Researchers study GO:0035194 to understand how cells fine-tune protein output and to harness RNAi for experimental and therapeutic applications. The discovery of RNAi revolutionized functional genomics by enabling targeted gene knockdown, and ongoing research continues to reveal new layers of regulation and disease connections.
regulatory ncRNA-mediated post-transcriptional gene silencing At A Glance
| GO ID | GO:0035194 |
|---|---|
| GO term | regulatory ncRNA-mediated post-transcriptional gene silencing |
| Ontology | biological_process |
| Synonym | RNA interference (RNAi), PTGS, cosuppression, quelling, post-transcriptional gene silencing by RNA |
| Major function | Sequence-specific silencing of target genes via mRNA destabilization or translational inhibition |
| Key molecular players | Dicer, Argonaute, TRBP, RISC components |
| Regulatory RNAs involved | siRNAs, miRNAs, piRNAs |
| Biological outcomes | Gene knockdown, antiviral defense, developmental regulation |
What Is GO:0035194?
GO:0035194 is defined as a posttranscriptional gene silencing pathway in which regulatory RNAs elicit silencing of specific target genes, either by mRNA destabilization or inhibition of translation. In simpler terms, it is the process by which small non-coding RNAs, such as small interfering RNAs (siRNAs) and microRNAs (miRNAs), guide the cell's machinery to reduce the expression of specific genes after their mRNAs have been made. This silencing can occur through cleavage and degradation of the target mRNA or by blocking its translation into protein.
Why Is regulatory ncRNA-mediated post-transcriptional gene silencing Important in Cell Biology?
GO:0035194 is critically important because it provides a versatile mechanism for controlling gene expression at the post-transcriptional level, influencing nearly every aspect of eukaryotic biology. It serves as a natural defense against viruses and transposable elements, and its dysregulation is linked to cancer, neurological disorders, and infectious diseases. Moreover, the RNAi pathway has been repurposed as a revolutionary research tool for gene function studies and as a therapeutic strategy, with several RNA-based drugs now approved or in clinical trials. Understanding this process at the molecular level is therefore essential for both basic biology and translational medicine.
• Enables sequence-specific gene knockdown for functional genomics studies.
• Plays a key role in antiviral defense and genome integrity.
• Regulates developmental timing and cell differentiation via microRNAs.
• Dysregulation is associated with cancer, neurodegeneration, and autoimmune diseases.
• Forms the basis for RNAi therapeutics, including siRNA drugs and miRNA mimics.
• Provides a tool for pest control through RNAi-based insecticides.
• Allows high-throughput screening to identify essential genes.
• Improves RNAi efficiency by modulating dsRNA nucleases.
• Facilitates ex vivo gene silencing for cell therapy applications.
• Serves as a model for understanding small RNA biogenesis and function.
What Happens During regulatory ncRNA-mediated post-transcriptional gene silencing?
Initiation: Production of small regulatory RNAs
In simple terms: The cell generates small RNA molecules that will guide the silencing machinery.
In the initiation stage, long double-stranded RNA (dsRNA) or primary microRNA transcripts are processed into small interfering RNAs (siRNAs) or microRNAs (miRNAs) by the RNase III enzyme Dicer. These small RNAs, typically 20-25 nucleotides in length, are then loaded into an Argonaute protein to form the RNA-induced silencing complex (RISC). The guide strand of the small RNA is retained, while the passenger strand is discarded, enabling sequence-specific recognition of target mRNAs.
Effector phase: Target recognition and silencing
In simple terms: The small RNA guides a protein complex to complementary mRNA, leading to gene silencing.
Once loaded into RISC, the guide RNA base-pairs with complementary sequences in the target mRNA. Perfect complementarity typically leads to Argonaute-mediated cleavage of the mRNA, which is then degraded by cellular exonucleases. In contrast, partial complementarity, common for miRNA targets, results in translational repression and/or mRNA destabilization through deadenylation and decapping. This dual mechanism allows for fine-tuned regulation of gene expression.
Amplification and systemic spread (in some organisms)
In simple terms: In some species, the silencing signal can be amplified and spread throughout the organism.
In plants, nematodes, and some insects, RNA-dependent RNA polymerases (RdRPs) can amplify the initial silencing trigger by synthesizing secondary siRNAs, leading to robust and systemic silencing. This amplification is crucial for antiviral defense and for the efficiency of RNAi in these organisms. In mammals, however, this amplification pathway is generally absent, and silencing is transient unless the small RNA is continuously supplied.
Regulation and turnover of silencing components
In simple terms: The silencing machinery itself is regulated to avoid unintended effects.
The activity of RISC components is tightly regulated through post-translational modifications, such as phosphorylation and ubiquitination, which affect Argonaute stability and small RNA loading. Additionally, the abundance of small RNAs is controlled by their biogenesis and degradation, ensuring that silencing is reversible and context-dependent. Dysregulation of these control mechanisms can lead to aberrant gene silencing and disease.
Key Genes Involved in GO:0035194 regulatory ncRNA-mediated post-transcriptional gene silencing
The following genes and proteins are core components or regulators of regulatory ncRNA-mediated post-transcriptional gene silencing (GO:0035194).
| Gene | Major Role | Research Relevance |
|---|---|---|
| DICER1 | RNase III enzyme that processes dsRNA into siRNAs and miRNAs | Essential for small RNA biogenesis; knockout abolishes RNAi |
| AGO2 | Core Argonaute protein that binds small RNAs and cleaves target mRNA | Key effector of RISC; knockdown reduces silencing efficiency |
| AGO1 | Argonaute protein involved in miRNA-mediated silencing | Important for developmental regulation and translational repression |
| TRBP | Double-stranded RNA-binding protein that assists Dicer and RISC loading | Modulates RNAi efficiency and HIV-1 replication |
| DGCR8 | Microprocessor complex component that binds pri-miRNAs | Required for miRNA maturation; knockout disrupts miRNA biogenesis |
| DROSHA | RNase III enzyme that cleaves pri-miRNAs in the nucleus | Essential for canonical miRNA processing |
| XPO5 | Exportin-5 that transports pre-miRNAs to the cytoplasm | Regulates miRNA availability; knockdown impairs RNAi |
| PIWIL1 | Piwi-family Argonaute protein involved in piRNA-mediated silencing | Important for germline genome defense |
| MOV10 | RNA helicase that associates with RISC and facilitates silencing | Modulates antiviral RNAi and retroelement silencing |
| TNRC6A | GW182 family protein that recruits deadenylation and decapping factors | Key downstream effector of miRNA-mediated silencing |
| DDX6 | RNA helicase involved in translational repression and mRNA decay | Required for miRNA-mediated silencing |
| EIF4E | Cap-binding protein that can be inhibited by miRNA silencing | Target of translational repression; affects protein synthesis |
| CNOT1 | Component of CCR4-NOT deadenylase complex | Mediates mRNA destabilization during silencing |
| GIGYF2 | Co-repressor that interacts with TNRC6 and inhibits translation | Plays a role in miRNA-mediated translational repression |
| UPF1 | Nonsense-mediated decay factor involved in RNAi off-target effects | Modulates silencing specificity |
| RISC complex | Multiprotein complex that executes silencing | Central to RNAi mechanism; target for functional studies |
| RdRP (in some species) | RNA-dependent RNA polymerase that amplifies silencing signals | Enhances RNAi efficiency in plants and insects |
How Is regulatory ncRNA-mediated post-transcriptional gene silencing Regulated?
The regulatory ncRNA-mediated post-transcriptional gene silencing pathway is regulated at multiple levels. Small RNA biogenesis is controlled by the availability of Dicer, Drosha, and their cofactors, which can be modulated by cellular signaling pathways. Argonaute proteins are subject to post-translational modifications, such as phosphorylation, that affect their stability and activity. Additionally, the abundance of target mRNAs and the presence of RNA-binding proteins can influence silencing efficiency. In some contexts, the pathway is regulated by interferon responses during viral infection, which can saturate or inhibit RNAi components. Understanding these regulatory mechanisms is crucial for optimizing RNAi-based experiments and therapeutics.
regulatory ncRNA-mediated post-transcriptional gene silencing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DICER1 | Pleuropulmonary blastoma, ovarian tumors | DICER1 knockout cell lines and mouse models |
| AGO2 | Cancer progression, antiviral defense | AGO2 knockout and point-mutation cell lines |
| TRBP | HIV-1 replication, cancer | TRBP knockout cells and viral infection assays |
| DGCR8 | DiGeorge syndrome, cancer | DGCR8 knockout stem cells and organoids |
| MOV10 | Retroviral infection, neurodevelopment | MOV10 overexpression and knockout neurons |
Cancer
Dysregulation of ncRNA-mediated silencing is frequently observed in cancer. For example, global downregulation of microRNAs is a common feature of many tumors, leading to overexpression of oncogenes. Mutations in DICER1 are associated with pleuropulmonary blastoma and other rare tumors. Additionally, components of the RNAi machinery such as AGO2 can act as tumor suppressors or oncogenes depending on context. Targeting the RNAi pathway is therefore an attractive therapeutic strategy.
Viral infections
RNA interference serves as a natural antiviral defense in plants and invertebrates, and viruses have evolved suppressors of RNAi to counteract this response. In mammals, the role of RNAi in antiviral immunity is more complex, but small RNAs can inhibit viral replication. For instance, TRBP is known to interact with HIV-1 TAR RNA and modulate viral replication. Understanding these interactions can inform the development of RNAi-based antiviral therapies.
Neurological disorders
MicroRNA dysregulation has been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's, where altered miRNA levels contribute to protein aggregation and neuronal death. For example, miR-29 and miR-107 are downregulated in Alzheimer's disease, leading to increased beta-secretase expression. Modulating RNAi pathways may offer therapeutic avenues for these conditions.
From regulatory ncRNA-mediated post-transcriptional gene silencing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DICER1 loss abolish RNAi? | DICER1 knockout cell line (e.g., HCT116) |
| What is the role of AGO2 catalytic activity in silencing? | AGO2 point-mutation (catalytic dead) knock-in |
| How does TRBP phosphorylation affect HIV-1 replication? | TRBP phospho-mutant knock-in T cells |
| Can miRNA overexpression suppress oncogenes? | miRNA overexpression lentiviral models |
| What genes are essential for RNAi in insects? | RNAi library screening in Drosophila cells |
| How does MOV10 affect retrotransposition? | MOV10 knockout and tagged knock-in HEK293 cells |
How to Study the regulatory ncRNA-mediated post-transcriptional gene silencing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA abundance and alternative splicing | Global transcriptome changes upon RNAi activation |
| Small RNA-seq | Small RNA expression profiles | miRNA/siRNA biogenesis and off-target analysis |
| Ribo-seq | Translation efficiency | Distinguishing translational repression from mRNA decay |
| Proteomics | Protein abundance and modifications | Validating silencing at the protein level |
| Luciferase reporter assay | Direct target repression | Testing miRNA/siRNA target sites |
| CLIP-seq | RNA-protein interactions | Mapping Argonaute binding sites |
| CRISPR screening | Gene essentiality and pathway components | Identifying novel RNAi factors |
RNA sequencing (RNA-seq)
RNA-seq is widely used to measure changes in mRNA abundance upon silencing. By comparing transcriptomes of cells with activated or inhibited RNAi pathways, researchers can identify direct and indirect targets. For example, RNA-seq after DICER1 knockout reveals global changes in miRNA target gene expression.
Small RNA sequencing
Small RNA-seq specifically profiles siRNAs, miRNAs, and piRNAs, providing insights into their biogenesis and abundance. This method is essential for studying the initiation stage of GO:0035194 and for validating the expression of designed siRNAs or miRNAs.
Ribosome profiling (Ribo-seq)
Ribo-seq measures translation efficiency by sequencing ribosome-protected mRNA fragments. It can distinguish between mRNA destabilization and translational inhibition, two outcomes of ncRNA-mediated silencing. This technique is particularly useful for studying miRNA-mediated repression.
Proteomics
Mass spectrometry-based proteomics can quantify protein-level changes that may not be evident from mRNA analysis alone, revealing the ultimate functional impact of silencing. It is often combined with RNA-seq for a multi-omics view.
How CRISPR Can Be Used to Study GO:0035194 regulatory ncRNA-mediated post-transcriptional gene silencing
Knockout
CRISPR knockout (KO) is used to completely ablate genes involved in GO:0035194, such as DICER1, AGO2, or TRBP, to study their essential roles in silencing. KO cell lines provide a clean background to test rescue experiments and to identify compensatory pathways. For example, DICER1 KO cells are widely used to study miRNA function.
Point Mutation
Point mutations can be introduced to dissect specific domains or catalytic residues. For instance, a catalytically dead AGO2 mutant (D669A) can be knocked into cells to separate slicing activity from miRNA binding. Such models are invaluable for understanding the precise molecular mechanisms of silencing.
Knock-in
Knock-in of tagged versions of proteins (e.g., GFP-AGO2) allows for live-cell imaging and proteomic analysis of RISC components. Additionally, knock-in of disease-associated mutations, such as those in DICER1, can model human disorders and test targeted therapies.
Overexpression
Overexpression of small RNAs or pathway components can enhance or perturb silencing. For example, lentiviral overexpression of a miRNA can suppress oncogenes in cancer models. Overexpression of dominant-negative mutants can also inhibit the pathway, providing a complementary approach to KO.
How EDITGENE Supports regulatory ncRNA-mediated post-transcriptional gene silencing Research
Researchers studying regulatory ncRNA-mediated post-transcriptional gene silencing-related genes often need to determine whether a candidate gene is causally involved in silencing, how its domains contribute to function, and whether its dysregulation drives disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for regulatory ncRNA-mediated post-transcriptional gene silencing research.
Frequently Asked Questions About regulatory ncRNA-mediated post-transcriptional gene silencing
What is GO:0035194?
GO:0035194 is the Gene Ontology term for regulatory ncRNA-mediated post-transcriptional gene silencing, a process where small non-coding RNAs like siRNAs and miRNAs silence specific genes by degrading mRNA or inhibiting translation.
What genes are involved in regulatory ncRNA-mediated post-transcriptional gene silencing?
Key genes include DICER1, AGO2, AGO1, TRBP, DGCR8, DROSHA, XPO5, and TNRC6A, among others.
How does RNA interference work?
RNA interference is triggered by double-stranded RNA, which is processed by Dicer into siRNAs. These siRNAs load into RISC, where Argonaute cleaves complementary mRNA, leading to gene silencing.
What is the difference between siRNA and miRNA?
siRNAs typically arise from exogenous long dsRNA and cause precise mRNA cleavage, while miRNAs are endogenous and usually repress translation or destabilize mRNA through partial complementarity.
What diseases are associated with defects in RNAi?
Defects in RNAi components are linked to cancer, viral infections, and neurological disorders such as Alzheimer's disease.
How can I study RNAi in the lab?
Common methods include RNA-seq, small RNA-seq, Ribo-seq, luciferase reporter assays, and CRISPR knockout of pathway genes.
What is the role of Argonaute proteins?
Argonaute proteins are the core effectors of RISC; they bind small RNAs and either cleave target mRNA or recruit factors for translational repression.
Can RNAi be used therapeutically?
Yes, RNAi-based drugs such as patisiran and givosiran have been approved, and many more are in clinical trials for genetic and infectious diseases.
How does CRISPR help study RNAi?
CRISPR knockout, knock-in, and point mutations allow precise manipulation of RNAi pathway genes to dissect their functions and model diseases.
What is the difference between transcriptional and post-transcriptional gene silencing?
Transcriptional silencing affects DNA or chromatin to prevent transcription, while post-transcriptional silencing, as in GO:0035194, acts on mRNA after it is made, affecting its stability or translation.
Conclusion
Regulatory ncRNA-mediated post-transcriptional gene silencing (GO:0035194) is a central mechanism of gene regulation with broad implications for basic biology and medicine. From its discovery as RNA interference to its current status as a therapeutic modality, this pathway continues to yield fundamental insights and clinical breakthroughs. Understanding its molecular players, regulatory mechanisms, and disease connections is essential for researchers across disciplines. With advanced CRISPR tools and bioinformatics, EDITGENE supports the scientific community in unraveling the complexities of this pathway and translating findings into new therapies.
References
- 1. Jadhav V et al.. 2024. RNA interference in the era of nucleic acid therapeutics.. Nat Biotechnol 42(3):394-405 PMID: 38409587
- 2. Downward J. 2004. RNA interference.. BMJ 328(7450):1245-8 PMID: 15155505
- 3. Sioud M. 2021. RNA Interference: Story and Mechanisms.. Methods Mol Biol 2282:1-15 PMID: 33928566
- 4. Dykxhoorn DM et al.. 2006. Silencing viral infection.. PLoS Med 3(7):e242 PMID: 16848617
- 5. Tayler A et al.. 2019. Efficiency of RNA interference is improved by knockdown of dsRNA nucleases in tephritid fruit flies.. Open Biol 9(12):190198 PMID: 31795920
- 6. Fischer SEJ. 2015. RNA Interference and MicroRNA-Mediated Silencing.. Curr Protoc Mol Biol 112:26.1.1-26.1.5 PMID: 26423588
- 7. Liu S. 2024. RNA Interference Ex Vivo.. Methods Mol Biol 2766:145-151 PMID: 38270874
- 8. Hu X et al.. 2022. A Random-Screening Approach to Identify RNAi Targets for the Control of Western Corn Rootworm (Diabrotica. virgifera virgifera Le Conte).. Methods Mol Biol 2360:91-103 PMID: 34495510
